Empfehlung
6,0
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | AtriCure, Inc. |
|---|---|
| Ticker | ATRC |
| CIK | 0001323885 |
Branche
| SIC-Code | 3841 |
|---|---|
| Beschreibung | Surgical & Medical Instruments & Apparatus |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | AtriCure, Inc. |
Status
| Zuletzt geprüft | 2026-03-25 05:37:19.908597 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 534,528,000 | -11,448,000 | -0.24 | 654,179,000 | 491,935,000 |
| 2018-12-31 | 10-K | 201,630,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-12 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -5,000 | 29.83 | -149,150.00 | -110,5% | |
| 2026-03-12 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -5,000 | 29.83 | -149,150.00 | -110,5% | |
| 2025-11-26 | Noznesky Justin J | Officer, Chief Mktg & Strategy Officer | Open Market Sale | -5,166 | 37.29 | -192,640.14 | -142,8% | |
| 2025-11-25 | WEHRWEIN SVEN | Director | Open Market Sale | -4,967 | 38.00 | -188,746.00 | -139,9% | |
| 2025-11-24 | WEHRWEIN SVEN | Director | Open Market Sale | -5,033 | 37.32 | -187,831.56 | -139,2% | |
| 2025-11-21 | Yuen Maggie | Director | Open Market Sale | -3,000 | 35.72 | -107,160.00 | -79,4% | |
| 2025-09-12 | Noznesky Justin J | Officer, Chief Mktg & Strategy Officer | Open Market Sale | -3,000 | 36.30 | -108,900.00 | -80,7% | |
| 2025-08-22 | WEHRWEIN SVEN | Director | Open Market Sale | -5,000 | 37.00 | -185,000.00 | -137,1% | |
| 2025-08-19 | WEHRWEIN SVEN | Director | Open Market Sale | -5,000 | 36.00 | -180,000.00 | -133,4% | |
| 2025-08-06 | GROVES REGINA E | Director | Open Market Sale | -2,452 | 36.82 | -90,282.64 | -66,9% | |
| 2025-08-05 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -2,500 | 36.58 | -91,450.00 | -67,8% | |
| 2025-08-05 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -2,500 | 36.58 | -91,450.00 | -67,8% | |
| 2025-05-28 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -2,500 | 33.44 | -83,600.00 | -62,0% | |
| 2025-05-28 | Doraiswamy Vinayak | Officer, Chief Scientific Officer | Open Market Sale | -2,500 | 33.44 | -83,600.00 | -62,0% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.